≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Tick-borne viral encephalitis

EFO Endpoint Browser PheWeb

AB1_TICK_BORNE_ENCEPHALITIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — A84
  • Hospital discharge: ICD-9 — 06[3]
  • Hospital discharge: ICD-8 — 06[3]
  • Cause of death: ICD-10 — A84
  • Cause of death: ICD-9 — 06[3]
  • Cause of death: ICD-8 — 06[3]

2 out of 7 registries used, show all original rules.

180

4. Check minimum number of events

None

180

5. Include endpoints

None

180

6. Filter based on genotype QC (FinnGen only)

164

Control definitions (FinnGen only)

Control exclude
AB1_VIRAL_CNS

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1177 458 710
Only index persons 1085 435 650
Unadjusted period prevalence (%)
Whole population 0.02 0.01 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 49.62 50.46 48.87
Only index persons 50.10 50.59 49.77

-FinnGen-

Key figures

All Female Male
Number of individuals 164 85 79
Unadjusted period prevalence (%) 0.03 0.03 0.04
Median age at first event (years) 56.77 54.50 59.20

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
180
Matched controls
1800
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A84.8
ICD-10 Finland
Other tick-borne viral encephalitis
+∞
95.5
83
*
A84.9
ICD-10 Finland
Tick-borne viral encephalitis, unspecified
+∞
84.1
74
*
A86
ICD-10 Finland
Unspecified viral encephalitis
+∞
39.0
36
*
XA800
NOMESCO Finland
Neuropsychological investigation
11.7
37.2
43
47
TAB00
NOMESCO Finland
Lumbar puncture
9.8
32.5
43
56
R50.9
ICD-10 Finland
Fever, unspecified
6.1
29.8
72
178
AA1AD
NOMESCO Finland
CT of head and brain
5.1
26.3
96
331
A87.9
ICD-10 Finland
Viral meningitis, unspecified
+∞
24.5
23
*
A84.1
ICD-10 Finland
Central European tick-borne encephalitis
+∞
23.4
22
*
A69.2
ICD-10 Finland
Lyme disease
7.9
21.7
33
50
R4120
NOMESCO Finland
Occupational therapy
6.4
18.9
35
65
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
13.7
13
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
11.6
35
98
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
10.8
111
644
N71
ICPC
Meningitis/encephalitis
+∞
10.5
10
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.5
10.3
22
29
A84
ICD-10 Finland
Tick-borne viral encephalitis
+∞
9.5
9
*
0632A
ICD-9 Finland
Tick-borne viral encephalitis, Central European encephalitis[PUUTIAISEN VÄLITTÄMÄ ENKEFALIITTI (KUMLINGE)]
+∞
9.5
9
*
B34.9
ICD-10 Finland
Viral infection, unspecified
9.1
8.0
16
19
G01*A69.2
ICD-10 Finland
Meningitis (in) Lyme disease
+∞
7.3
7
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
21.0
7.2
10
5
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.2
7.1
31
110
G03.9
ICD-10 Finland
Meningitis, unspecified
23.5
6.7
9
*
N29
ICPC
Neurological sympt/complt other
11.6
6.4
11
10
S12
ICPC
Insect bite/sting
3.1
6.0
27
97
J01CA04
ATC
amoxicillin; systemic
3.0
6.0
157
1252

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1.9e-01
9.8e-02
3.2e+00
5.3e+00
3.0e+00
4.2e-01
7.7e-02
cases:45.93%
controls:41.36%
cases:27.33%
controls:25.42%
cases:54.07%
controls:4.54%
cases:44.77%
controls:0.41%
cases:53.25%
controls:5.20%
cases:33.33%
controls:24.69%
cases:44.44%
controls:42.56%
79
711
93
1008
47
437
125
1282
93
78
79
1641
77
7
95
1712
90
89
79
1624
53
398
106
1214
52
483
65
652
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.3e-01
3.3e-01
2.9e+00
5.4e+00
2.9e+00
3.9e-01
-5.9e-02
cases:50.58%
controls:44.74%
cases:38.37%
controls:31.01%
cases:49.42%
controls:5.24%
cases:44.77%
controls:0.35%
cases:53.25%
controls:5.90%
cases:40.88%
controls:31.82%
cases:50.43%
controls:51.89%
87
769
85
950
66
533
106
1186
85
90
87
1629
77
6
95
1713
90
101
79
1612
65
513
94
1099
59
589
58
546
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.4e-01
3.1e-01
2.8e+00
5.4e+00
2.9e+00
4.0e-01
-6.9e-02
cases:51.16%
controls:45.26%
cases:38.37%
controls:31.41%
cases:49.42%
controls:5.47%
cases:44.77%
controls:0.35%
cases:53.85%
controls:5.95%
cases:41.51%
controls:32.32%
cases:50.43%
controls:52.16%
88
778
84
941
66
540
106
1179
85
94
87
1625
77
6
95
1713
91
102
78
1611
66
521
93
1091
59
592
58
543
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.3e-01
3.1e-01
2.6e+00
5.1e+00
2.6e+00
3.4e-01
-1.7e-01
cases:53.49%
controls:50.20%
cases:44.77%
controls:37.17%
cases:51.16%
controls:7.33%
cases:43.02%
controls:0.47%
cases:52.07%
controls:7.65%
cases:45.91%
controls:37.59%
cases:52.99%
controls:57.09%
92
863
80
856
77
639
95
1080
88
126
84
1593
74
8
98
1711
88
131
81
1582
73
606
86
1006
62
648
55
487
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.0e-01
4.6e-01
2.7e+00
4.9e+00
2.6e+00
5.3e-01
-1.3e-01
cases:44.77%
controls:37.46%
cases:38.37%
controls:28.16%
cases:45.93%
controls:5.47%
cases:34.88%
controls:0.41%
cases:43.79%
controls:5.49%
cases:40.25%
controls:28.47%
cases:40.17%
controls:43.26%
77
644
95
1075
66
484
106
1235
79
94
93
1625
60
7
112
1712
74
94
95
1619
64
459
95
1153
47
491
70
644
Neurology
13 [38004458]
-4.6e-01
3.1e-01
2.4e+00
1.0e+50
4.4e+00
3.2e+00
6.6e-01
cases:7.56%
controls:11.46%
cases:6.40%
controls:4.77%
cases:11.05%
controls:1.11%
cases:58.14%
controls:0.00%
cases:33.73%
controls:0.64%
cases:52.20%
controls:4.09%
cases:16.24%
controls:9.07%
13
197
159
1522
11
82
161
1637
19
19
153
1700
100
0
72
1719
57
11
112
1702
83
66
76
1546
19
103
98
1032
MCH [Entitic mass]
28539-5 [3035941]
1.6e-01
3.0e-01
2.5e+00
4.6e+00
2.6e+00
3.8e-01
-9.8e-02
cases:58.72%
controls:54.74%
cases:48.84%
controls:41.30%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.81%
cases:50.31%
controls:40.94%
cases:58.97%
controls:61.32%
101
941
71
778
84
710
88
1009
93
154
79
1565
76
13
96
1706
94
151
75
1562
80
660
79
952
69
696
48
439
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.6e-01
3.0e-01
2.5e+00
4.6e+00
2.6e+00
3.7e-01
-1.0e-01
cases:58.72%
controls:54.80%
cases:48.84%
controls:41.48%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.81%
cases:50.31%
controls:41.13%
cases:58.97%
controls:61.41%
101
942
71
777
84
713
88
1006
93
154
79
1565
76
13
96
1706
94
151
75
1562
80
663
79
949
69
697
48
438
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.6e-01
3.0e-01
2.5e+00
4.6e+00
2.6e+00
3.7e-01
-1.0e-01
cases:58.72%
controls:54.80%
cases:48.84%
controls:41.48%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.81%
cases:50.31%
controls:41.13%
cases:58.97%
controls:61.41%
101
942
71
777
84
713
88
1006
93
154
79
1565
76
13
96
1706
94
151
75
1562
80
663
79
949
69
697
48
438
Platelets [#/volume] in Blood
26515-7 [3007461]
1.4e-01
3.0e-01
2.5e+00
4.6e+00
2.6e+00
3.8e-01
-9.1e-02
cases:58.14%
controls:54.68%
cases:48.84%
controls:41.42%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.81%
cases:50.31%
controls:40.94%
cases:58.97%
controls:61.15%
100
940
72
779
84
712
88
1007
93
154
79
1565
76
13
96
1706
94
151
75
1562
80
660
79
952
69
694
48
441
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.6e-01
3.0e-01
2.5e+00
4.6e+00
2.6e+00
3.7e-01
-1.0e-01
cases:58.72%
controls:54.80%
cases:48.84%
controls:41.36%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.81%
cases:50.31%
controls:41.07%
cases:58.97%
controls:61.41%
101
942
71
777
84
711
88
1008
93
154
79
1565
76
13
96
1706
94
151
75
1562
80
662
79
950
69
697
48
438
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.6e-01
3.0e-01
2.5e+00
4.6e+00
2.5e+00
3.7e-01
-1.0e-01
cases:58.72%
controls:54.92%
cases:48.84%
controls:41.54%
cases:54.07%
controls:8.96%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.93%
cases:50.31%
controls:41.19%
cases:58.97%
controls:61.41%
101
944
71
775
84
714
88
1005
93
154
79
1565
76
13
96
1706
94
153
75
1560
80
664
79
948
69
697
48
438
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.6e-01
2.9e-01
2.5e+00
4.6e+00
2.5e+00
3.6e-01
-1.0e-01
cases:58.72%
controls:54.74%
cases:48.84%
controls:41.59%
cases:54.07%
controls:9.02%
cases:44.19%
controls:0.76%
cases:55.62%
controls:8.93%
cases:50.31%
controls:41.38%
cases:58.97%
controls:61.41%
101
941
71
778
84
715
88
1004
93
155
79
1564
76
13
96
1706
94
153
75
1560
80
667
79
945
69
697
48
438
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
2.7e-01
4.2e-01
2.4e+00
4.3e+00
2.6e+00
3.5e-01
-1.7e-01
cases:47.09%
controls:40.37%
cases:35.47%
controls:26.53%
cases:37.79%
controls:5.41%
cases:31.40%
controls:0.64%
cases:40.83%
controls:4.90%
cases:33.96%
controls:26.55%
cases:40.17%
controls:44.23%
81
694
91
1025
61
456
111
1263
65
93
107
1626
54
11
118
1708
69
84
100
1629
54
428
105
1184
47
502
70
633
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.8e-01
3.0e-01
2.3e+00
4.1e+00
2.4e+00
3.1e-01
-8.2e-02
cases:43.02%
controls:36.36%
cases:32.56%
controls:26.41%
cases:37.21%
controls:5.64%
cases:28.49%
controls:0.64%
cases:40.24%
controls:5.55%
cases:32.08%
controls:25.74%
cases:37.61%
controls:39.56%
74
625
98
1094
56
454
116
1265
64
97
108
1622
49
11
123
1708
68
95
101
1618
51
415
108
1197
44
449
73
686
Laboratory Visit
OMOP4822461 [32036]
4.5e-02
3.5e-01
2.0e+00
4.3e+00
2.0e+00
2.1e-01
-1.3e-02
cases:61.05%
controls:59.98%
cases:61.05%
controls:52.36%
cases:58.72%
controls:16.64%
cases:54.07%
controls:1.51%
cases:57.99%
controls:16.17%
cases:56.60%
controls:51.43%
cases:64.10%
controls:64.41%
105
1031
67
688
105
900
67
819
101
286
71
1433
93
26
79
1693
98
277
71
1436
90
829
69
783
75
731
42
404
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.9e-01
7.3e-01
3.5e+00
1.0e+50
3.6e+00
5.7e-01
8.0e-02
cases:11.63%
controls:6.81%
cases:6.40%
controls:3.20%
cases:12.21%
controls:0.41%
cases:13.37%
controls:0.00%
cases:15.98%
controls:0.53%
cases:5.03%
controls:2.92%
cases:6.84%
controls:6.34%
20
117
152
1602
11
55
161
1664
21
7
151
1712
23
0
149
1719
27
9
142
1704
8
47
151
1565
8
72
109
1063
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.1e-01
—
3.6e+00
1.0e+50
3.5e+00
2.4e-01
-1.0e-01
cases:8.14%
controls:7.33%
—
—
cases:11.63%
controls:0.35%
cases:5.81%
controls:0.00%
cases:10.06%
controls:0.35%
cases:3.77%
controls:2.98%
cases:7.69%
controls:8.46%
14
126
158
1593
—
20
6
152
1713
10
0
162
1719
17
6
152
1707
6
48
153
1564
9
96
108
1039
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
4.4e-01
3.6e-01
3.8e+00
—
3.1e+00
—
2.2e-01
cases:5.81%
controls:3.84%
cases:2.91%
controls:2.04%
cases:11.63%
controls:0.29%
—
—
cases:5.92%
controls:0.29%
—
—
cases:5.98%
controls:4.85%
10
66
162
1653
5
35
167
1684
20
5
152
1714
—
10
5
159
1708
—
7
55
110
1080
Internal Medicine
11 [38004456]
4.9e-02
6.1e-01
3.2e+00
—
2.4e+00
1.2e+00
1.6e-01
cases:19.19%
controls:18.44%
cases:11.63%
controls:6.69%
cases:19.77%
controls:0.99%
—
—
cases:11.24%
controls:1.11%
cases:15.72%
controls:5.27%
cases:18.80%
controls:16.48%
33
317
139
1402
20
115
152
1604
34
17
138
1702
—
19
19
150
1694
25
85
134
1527
22
187
95
948
doxycycline; oral, parenteral
J01AA02 [21602800]
2.4e-01
1.4e-02
3.2e+00
—
3.4e+00
2.8e-02
2.2e-01
cases:16.86%
controls:13.79%
cases:4.07%
controls:4.01%
cases:8.14%
controls:0.35%
—
—
cases:8.28%
controls:0.29%
cases:5.03%
controls:4.90%
cases:15.38%
controls:12.78%
29
237
143
1482
7
69
165
1650
14
6
158
1713
—
14
5
155
1708
8
79
151
1533
18
145
99
990
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.0e-01
6.4e-01
3.5e+00
—
3.0e+00
4.6e-01
-1.8e-01
cases:11.05%
controls:6.98%
cases:6.40%
controls:3.49%
cases:16.86%
controls:0.58%
—
—
cases:11.24%
controls:0.64%
cases:5.03%
controls:3.23%
cases:6.84%
controls:8.11%
19
120
153
1599
11
60
161
1659
29
10
143
1709
—
19
11
150
1702
8
52
151
1560
8
92
109
1043
Bacteria [Presence] in Urine
87829-8 [36304419]
5.7e-01
6.9e-01
3.5e+00
—
3.0e+00
4.7e-01
-1.1e-01
cases:11.63%
controls:6.92%
cases:6.40%
controls:3.32%
cases:15.70%
controls:0.58%
—
—
cases:10.06%
controls:0.53%
cases:4.40%
controls:2.79%
cases:6.84%
controls:7.58%
20
119
152
1600
11
57
161
1662
27
10
145
1709
—
17
9
152
1704
7
45
152
1567
8
86
109
1049
Differential panel, method unspecified - Blood
69738-3 [42870588]
5.0e-01
2.4e-01
3.0e+00
—
3.4e+00
8.2e-01
2.8e-01
cases:15.70%
controls:10.18%
cases:7.56%
controls:6.05%
cases:16.28%
controls:0.99%
—
—
cases:21.89%
controls:0.93%
cases:11.95%
controls:5.65%
cases:12.82%
controls:10.04%
27
175
145
1544
13
104
159
1615
28
17
144
1702
—
37
16
132
1697
19
91
140
1521
15
114
102
1021
INR in Blood by Coagulation assay
34714-6 [3032080]
-1.6e-01
2.5e-01
1.9e+00
2.9e+00
1.5e+00
3.9e-01
-8.8e-02
cases:11.05%
controls:12.74%
cases:8.72%
controls:6.92%
cases:14.53%
controls:2.44%
cases:5.23%
controls:0.29%
cases:8.88%
controls:2.16%
cases:8.81%
controls:6.14%
cases:12.82%
controls:13.83%
19
219
153
1500
15
119
157
1600
25
42
147
1677
9
5
163
1714
15
37
154
1676
14
99
145
1513
15
157
102
978
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
3.3e-01
8.1e-02
3.3e+00
—
2.9e+00
2.8e-01
-2.2e-01
cases:12.21%
controls:9.08%
cases:4.65%
controls:4.30%
cases:18.02%
controls:0.81%
—
—
cases:11.83%
controls:0.70%
cases:5.03%
controls:3.85%
cases:8.55%
controls:10.40%
21
156
151
1563
8
74
164
1645
31
14
141
1705
—
20
12
149
1701
8
62
151
1550
10
118
107
1017
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
5.2e-01
7.4e-01
3.5e+00
—
2.7e+00
—
1.5e-01
cases:6.40%
controls:3.90%
cases:4.65%
controls:2.27%
cases:12.21%
controls:0.41%
—
—
cases:6.51%
controls:0.47%
—
—
cases:5.98%
controls:5.20%
11
67
161
1652
8
39
164
1680
21
7
151
1712
—
11
8
158
1705
—
7
59
110
1076
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
3.3e-01
6.0e-01
3.3e+00
—
2.9e+00
2.8e-01
-2.7e-01
cases:11.05%
controls:8.20%
cases:6.98%
controls:3.96%
cases:18.60%
controls:0.81%
—
—
cases:11.83%
controls:0.76%
cases:5.03%
controls:3.85%
cases:7.69%
controls:9.87%
19
141
153
1578
12
68
160
1651
32
14
140
1705
—
20
13
149
1700
8
62
151
1550
9
112
108
1023
Emergency Room and Inpatient Visit
ERIP [262]
-6.5e-02
6.2e-01
3.1e+00
1.0e+50
2.8e+00
2.2e-01
-1.4e-01
cases:7.56%
controls:8.03%
cases:5.81%
controls:3.20%
cases:8.72%
controls:0.41%
cases:37.21%
controls:0.00%
cases:8.28%
controls:0.53%
cases:5.03%
controls:4.09%
cases:8.55%
controls:9.69%
13
138
159
1581
10
55
162
1664
15
7
157
1712
64
0
108
1719
14
9
155
1704
8
66
151
1546
10
110
107
1025
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.4e-01
1.6e-01
2.9e+00
—
3.1e+00
7.3e-01
-1.5e-01
cases:20.35%
controls:15.42%
cases:10.47%
controls:9.08%
cases:20.93%
controls:1.45%
—
—
cases:27.22%
controls:1.69%
cases:15.09%
controls:7.88%
cases:13.68%
controls:15.59%
35
265
137
1454
18
156
154
1563
36
25
136
1694
—
46
29
123
1684
24
127
135
1485
16
177
101
958
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.3e-01
1.6e-01
2.9e+00
—
3.0e+00
7.4e-01
-1.5e-01
cases:20.35%
controls:15.53%
cases:10.47%
controls:9.02%
cases:20.93%
controls:1.40%
—
—
cases:26.63%
controls:1.75%
cases:15.09%
controls:7.82%
cases:13.68%
controls:15.51%
35
267
137
1452
18
155
154
1564
36
24
136
1695
—
45
30
124
1683
24
126
135
1486
16
176
101
959
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.3e-01
1.5e-01
2.9e+00
—
3.0e+00
7.4e-01
-1.3e-01
cases:20.35%
controls:15.47%
cases:10.47%
controls:9.13%
cases:20.93%
controls:1.40%
—
—
cases:26.63%
controls:1.75%
cases:15.09%
controls:7.82%
cases:13.68%
controls:15.24%
35
266
137
1453
18
157
154
1562
36
24
136
1695
—
45
30
124
1683
24
126
135
1486
16
173
101
962
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.3e-01
1.4e-01
2.9e+00
—
3.0e+00
6.8e-01
-1.6e-01
cases:19.19%
controls:15.88%
cases:10.47%
controls:9.25%
cases:21.51%
controls:1.51%
—
—
cases:26.63%
controls:1.75%
cases:15.09%
controls:8.25%
cases:13.68%
controls:15.68%
33
273
139
1446
18
159
154
1560
37
26
135
1693
—
45
30
124
1683
24
133
135
1479
16
178
101
957
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.1e-01
6.0e-01
3.3e+00
—
2.6e+00
1.4e-03
-4.3e-01
cases:15.12%
controls:9.66%
cases:9.30%
controls:5.35%
cases:20.35%
controls:0.93%
—
—
cases:11.24%
controls:0.93%
cases:5.03%
controls:5.02%
cases:7.69%
controls:11.37%
26
166
146
1553
16
92
156
1627
35
16
137
1703
—
19
16
150
1697
8
81
151
1531
9
129
108
1006
Basophils [#/volume] in Blood
26444-0 [3006315]
4.0e-01
-6.5e-04
2.9e+00
—
3.0e+00
6.4e-01
-1.9e-01
cases:22.67%
controls:16.46%
cases:9.88%
controls:9.89%
cases:22.67%
controls:1.57%
—
—
cases:27.22%
controls:1.87%
cases:15.72%
controls:9.00%
cases:14.53%
controls:17.00%
39
283
133
1436
17
170
155
1549
39
27
133
1692
—
46
32
123
1681
25
145
134
1467
17
193
100
942
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.8e-01
4.4e-02
2.9e+00
—
3.0e+00
5.9e-01
-1.3e-01
cases:22.67%
controls:16.64%
cases:10.47%
controls:10.06%
cases:23.26%
controls:1.63%
—
—
cases:27.81%
controls:1.93%
cases:15.72%
controls:9.37%
cases:15.38%
controls:17.09%
39
286
133
1433
18
173
154
1546
40
28
132
1691
—
47
33
122
1680
25
151
134
1461
18
194
99
941
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.9e-01
4.6e-02
2.9e+00
—
3.0e+00
7.1e-01
-1.9e-01
cases:20.35%
controls:16.00%
cases:9.88%
controls:9.48%
cases:21.51%
controls:1.51%
—
—
cases:26.63%
controls:1.81%
cases:15.09%
controls:8.06%
cases:13.68%
controls:16.04%
35
275
137
1444
17
163
155
1556
37
26
135
1693
—
45
31
124
1682
24
130
135
1482
16
182
101
953
Monocytes [#/volume] in Blood
26484-6 [3001604]
4.1e-01
-7.2e-03
2.9e+00
—
3.0e+00
6.4e-01
-1.7e-01
cases:22.67%
controls:16.35%
cases:9.88%
controls:9.95%
cases:22.09%
controls:1.57%
—
—
cases:27.22%
controls:1.87%
cases:15.72%
controls:9.00%
cases:14.53%
controls:16.83%
39
281
133
1438
17
171
155
1548
38
27
134
1692
—
46
32
123
1681
25
145
134
1467
17
191
100
944
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.6e-01
-4.6e-02
2.9e+00
—
2.9e+00
6.1e-01
-2.1e-01
cases:22.67%
controls:17.04%
cases:9.88%
controls:10.30%
cases:23.26%
controls:1.63%
—
—
cases:27.22%
controls:1.93%
cases:15.72%
controls:9.18%
cases:14.53%
controls:17.36%
39
293
133
1426
17
177
155
1542
40
28
132
1691
—
46
33
123
1680
25
148
134
1464
17
197
100
938
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.0e-01
4.7e-01
3.3e+00
—
2.4e+00
1.1e-01
1.1e-01
cases:27.33%
controls:20.19%
cases:12.79%
controls:8.44%
cases:32.56%
controls:1.69%
—
—
cases:12.43%
controls:1.28%
cases:8.81%
controls:7.94%
cases:21.37%
controls:19.65%
47
347
125
1372
22
145
150
1574
56
29
116
1690
—
21
22
148
1691
14
128
145
1484
25
223
92
912
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
2.8e-01
2.7e-01
3.1e+00
—
2.6e+00
4.1e-01
1.3e-01
cases:15.70%
controls:12.33%
cases:7.56%
controls:5.88%
cases:12.21%
controls:0.64%
—
—
cases:9.47%
controls:0.76%
cases:8.81%
controls:6.02%
cases:14.53%
controls:13.04%
27
212
145
1507
13
101
159
1618
21
11
151
1708
—
16
13
153
1700
14
97
145
1515
17
148
100
987
Inpatient Hospital
21 [8717]
2.6e-02
3.8e-01
2.9e+00
1.0e+50
2.8e+00
4.6e-01
-3.7e-02
cases:22.67%
controls:22.22%
cases:10.47%
controls:7.39%
cases:12.79%
controls:0.81%
cases:31.98%
controls:0.00%
cases:11.83%
controls:0.82%
cases:8.81%
controls:5.77%
cases:17.09%
controls:17.62%
39
382
133
1337
18
127
154
1592
22
14
150
1705
55
0
117
1719
20
14
149
1699
14
93
145
1519
20
200
97
935
pH of Serum or Plasma
2753-2 [3018418]
3.3e-01
—
2.9e+00
—
2.7e+00
6.9e-01
-4.4e-02
cases:10.47%
controls:7.74%
—
—
cases:5.81%
controls:0.35%
—
—
cases:6.51%
controls:0.47%
cases:6.92%
controls:3.60%
cases:8.55%
controls:8.90%
18
133
154
1586
—
10
6
162
1713
—
11
8
158
1705
11
58
148
1554
10
101
107
1034
Supplier / Service Provider
OMOP5117446 [33004]
-4.6e-01
-6.3e-01
—
—
—
2.7e+00
2.8e+00
cases:22.67%
controls:31.70%
cases:4.65%
controls:8.38%
—
—
—
—
—
—
cases:6.92%
controls:0.50%
cases:14.53%
controls:0.97%
39
545
133
1174
8
144
164
1575
—
—
—
11
8
148
1604
17
11
100
1124
Emergency Medicine
93 [38004510]
-1.5e-01
4.5e-01
3.9e+00
—
1.7e+00
-8.9e-02
2.2e-01
cases:19.19%
controls:21.58%
cases:15.12%
controls:10.24%
cases:34.88%
controls:1.11%
—
—
cases:4.73%
controls:0.93%
cases:7.55%
controls:8.19%
cases:27.35%
controls:23.26%
33
371
139
1348
26
176
146
1543
60
19
112
1700
—
8
16
161
1697
12
132
147
1480
32
264
85
871
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-6.3e-02
1.3e-01
3.3e+00
—
2.2e+00
3.5e-01
-2.9e-01
cases:16.28%
controls:17.16%
cases:7.56%
controls:6.69%
cases:20.35%
controls:0.93%
—
—
cases:8.88%
controls:1.05%
cases:8.81%
controls:6.39%
cases:13.68%
controls:17.44%
28
295
144
1424
13
115
159
1604
35
16
137
1703
—
15
18
154
1695
14
103
145
1509
16
198
101
937
Emergency Room Visit
ER [9203]
2.1e-01
6.0e-01
3.3e+00
—
2.1e+00
-1.5e-01
1.4e-01
cases:32.56%
controls:28.16%
cases:14.53%
controls:8.55%
cases:22.09%
controls:0.99%
—
—
cases:8.88%
controls:1.17%
cases:6.29%
controls:7.26%
cases:25.64%
controls:23.08%
56
484
116
1235
25
147
147
1572
38
17
134
1702
—
15
20
154
1693
10
117
149
1495
30
262
87
873
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.2e-01
9.5e-02
2.7e+00
—
2.7e+00
5.5e-01
7.5e-02
cases:25.58%
controls:18.50%
cases:12.21%
controls:11.23%
cases:23.84%
controls:2.09%
—
—
cases:27.22%
controls:2.39%
cases:15.72%
controls:9.74%
cases:19.66%
controls:18.50%
44
318
128
1401
21
193
151
1526
41
36
131
1683
—
46
41
123
1672
25
157
134
1455
23
210
94
925
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.0e-01
5.1e-01
2.9e+00
1.0e+50
2.5e+00
5.3e-01
4.8e-01
cases:18.60%
controls:13.32%
cases:10.47%
controls:6.57%
cases:16.28%
controls:1.05%
cases:9.30%
controls:0.00%
cases:13.02%
controls:1.23%
cases:10.06%
controls:6.20%
cases:22.22%
controls:14.98%
32
229
140
1490
18
113
154
1606
28
18
144
1701
16
0
156
1719
22
21
147
1692
16
100
143
1512
26
170
91
965
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.4e-01
2.3e-01
3.2e+00
—
2.1e+00
3.0e-01
-6.5e-02
cases:25.58%
controls:22.98%
cases:12.21%
controls:9.95%
cases:26.74%
controls:1.51%
—
—
cases:10.06%
controls:1.34%
cases:11.32%
controls:8.62%
cases:19.66%
controls:20.70%
44
395
128
1324
21
171
151
1548
46
26
126
1693
—
17
23
152
1690
18
139
141
1473
23
235
94
900
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.6e-01
1.1e-01
2.7e+00
—
2.4e+00
4.4e-01
-5.6e-02
cases:16.28%
controls:14.25%
cases:7.56%
controls:6.81%
cases:10.47%
controls:0.76%
—
—
cases:10.06%
controls:0.99%
cases:10.69%
controls:7.13%
cases:14.53%
controls:15.24%
28
245
144
1474
13
117
159
1602
18
13
154
1706
—
17
17
152
1696
17
115
142
1497
17
173
100
962
Case Management Agency
251B00000X [38004193]
-1.1e-01
7.2e-02
1.2e+00
3.3e+00
5.9e-01
3.7e-01
-5.3e-02
cases:71.51%
controls:73.71%
cases:70.35%
controls:68.82%
cases:61.05%
controls:32.05%
cases:36.63%
controls:2.04%
cases:43.79%
controls:30.18%
cases:76.10%
controls:68.73%
cases:77.78%
controls:78.68%
123
1267
49
452
121
1183
51
536
105
551
67
1168
63
35
109
1684
74
517
95
1196
121
1108
38
504
91
893
26
242
Short blood count panel - Blood
55429-5 [40758558]
4.9e-01
5.4e-01
2.3e+00
—
2.8e+00
8.2e-01
4.4e-01
cases:10.47%
controls:6.69%
cases:6.40%
controls:3.84%
cases:7.56%
controls:0.81%
—
—
cases:8.88%
controls:0.58%
cases:6.92%
controls:3.16%
cases:12.82%
controls:8.63%
18
115
154
1604
11
66
161
1653
13
14
159
1705
—
15
10
154
1703
11
51
148
1561
15
98
102
1037
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.8e-01
4.1e-01
2.8e+00
—
2.2e+00
3.9e-01
3.4e-01
cases:30.23%
controls:26.64%
cases:19.77%
controls:14.02%
cases:26.16%
controls:2.09%
—
—
cases:23.67%
controls:3.27%
cases:20.75%
controls:15.07%
cases:35.04%
controls:27.75%
52
458
120
1261
34
241
138
1478
45
36
127
1683
—
40
56
129
1657
33
243
126
1369
41
315
76
820
naproxcinod
M01AE18 [40254094]
-9.9e-02
2.7e-01
2.3e+00
—
2.7e+00
—
1.2e-01
cases:8.72%
controls:9.54%
cases:3.49%
controls:2.68%
cases:3.49%
controls:0.35%
—
—
cases:4.14%
controls:0.29%
—
—
cases:8.55%
controls:7.67%
15
164
157
1555
6
46
166
1673
6
6
166
1713
—
7
5
162
1708
—
10
87
107
1048
naproxen; oral, rectal
M01AE02 [21603968]
-9.9e-02
2.7e-01
2.3e+00
—
2.7e+00
—
1.2e-01
cases:8.72%
controls:9.54%
cases:3.49%
controls:2.68%
cases:3.49%
controls:0.35%
—
—
cases:4.14%
controls:0.29%
—
—
cases:8.55%
controls:7.67%
15
164
157
1555
6
46
166
1673
6
6
166
1713
—
7
5
162
1708
—
10
87
107
1048
Outpatient Visit
OP [9202]
1.1e-01
-1.1e-02
-3.0e-01
3.9e+00
9.5e-01
3.9e-01
-1.2e-01
cases:78.49%
controls:76.61%
cases:54.65%
controls:54.92%
cases:7.56%
controls:9.95%
cases:12.79%
controls:0.29%
cases:22.49%
controls:10.10%
cases:60.38%
controls:50.81%
cases:73.50%
controls:75.68%
135
1317
37
402
94
944
78
775
13
171
159
1548
22
5
150
1714
38
173
131
1540
96
819
63
793
86
859
31
276
Normoblasts [#/volume] in Blood
715-3 [3021589]
3.1e-01
-3.6e-02
2.3e+00
—
2.6e+00
3.5e-01
-4.2e-01
cases:19.19%
controls:14.89%
cases:11.05%
controls:11.40%
cases:19.77%
controls:2.44%
—
—
cases:25.44%
controls:2.57%
cases:14.47%
controls:10.61%
cases:11.11%
controls:16.04%
33
256
139
1463
19
196
153
1523
34
42
138
1677
—
43
44
126
1669
23
171
136
1441
13
182
104
953
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.7e-02
-1.4e-01
2.6e+00
1.0e+50
2.2e+00
5.2e-01
3.3e-03
cases:27.91%
controls:27.17%
cases:11.05%
controls:12.45%
cases:20.35%
controls:1.80%
cases:5.81%
controls:0.00%
cases:15.98%
controls:2.04%
cases:18.24%
controls:11.72%
cases:26.50%
controls:26.43%
48
467
124
1252
19
214
153
1505
35
31
137
1688
10
0
162
1719
27
35
142
1678
29
189
130
1423
31
300
86
835
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
7.6e-02
7.4e-01
2.5e+00
—
2.4e+00
3.0e-01
—
cases:5.81%
controls:5.41%
cases:4.07%
controls:1.98%
cases:6.40%
controls:0.58%
—
—
cases:5.33%
controls:0.53%
cases:3.14%
controls:2.36%
—
—
10
93
162
1626
7
34
165
1685
11
10
161
1709
—
9
9
160
1704
5
38
154
1574
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
3.9e-01
5.1e-01
2.7e+00
—
2.0e+00
—
—
cases:8.72%
controls:6.05%
cases:6.40%
controls:3.96%
cases:9.88%
controls:0.70%
—
—
cases:4.73%
controls:0.64%
—
—
—
—
15
104
157
1615
11
68
161
1651
17
12
155
1707
—
8
11
161
1702
—
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
8.6e-02
1.5e-01
2.5e+00
—
2.0e+00
-3.6e-02
-7.4e-01
cases:7.56%
controls:6.98%
cases:4.65%
controls:4.01%
cases:9.88%
controls:0.87%
—
—
cases:4.14%
controls:0.58%
cases:3.77%
controls:3.91%
cases:4.27%
controls:8.55%
13
120
159
1599
8
69
164
1650
17
15
155
1704
—
7
10
162
1703
6
63
153
1549
5
97
112
1038
Thorax X-ray examination
GD1AA [2001303617]
-2.7e-01
3.2e-01
4.5e+00
—
—
2.2e-01
4.9e-01
cases:6.98%
controls:8.96%
cases:4.65%
controls:3.43%
cases:20.35%
controls:0.29%
—
—
—
—
cases:3.77%
controls:3.04%
cases:11.97%
controls:7.67%
12
154
160
1565
8
59
164
1660
35
5
137
1714
—
—
6
49
153
1563
14
87
103
1048
CBC panel - Blood by Automated count
58410-2 [40761511]
1.2e-01
6.9e-02
2.2e+00
—
2.1e+00
1.8e-01
-6.9e-02
cases:48.84%
controls:45.84%
cases:26.74%
controls:25.42%
cases:29.07%
controls:4.48%
—
—
cases:28.99%
controls:4.96%
cases:28.93%
controls:25.43%
cases:43.59%
controls:45.29%
84
788
88
931
46
437
126
1282
50
77
122
1642
—
49
85
120
1628
46
410
113
1202
51
514
66
621
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
4.1e-02
-3.4e-01
2.1e+00
—
2.1e+00
2.8e-01
-5.2e-01
cases:11.05%
controls:10.65%
cases:3.49%
controls:4.83%
cases:4.65%
controls:0.58%
—
—
cases:4.14%
controls:0.53%
cases:6.29%
controls:4.84%
cases:6.84%
controls:11.01%
19
183
153
1536
6
83
166
1636
8
10
164
1709
—
7
9
162
1704
10
78
149
1534
8
125
109
1010
General Practice
1 [38004446]
4.0e-02
—
2.2e+00
1.0e+50
2.0e+00
—
-3.5e-01
cases:11.63%
controls:11.23%
—
—
cases:5.81%
controls:0.70%
cases:4.07%
controls:0.00%
cases:5.92%
controls:0.82%
—
—
cases:7.69%
controls:10.57%
20
193
152
1526
—
10
12
162
1707
7
0
165
1719
10
14
159
1699
—
9
120
108
1015
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.8e-01
3.3e-01
2.1e+00
—
2.1e+00
3.3e-01
-1.7e-01
cases:54.65%
controls:47.64%
cases:41.28%
controls:33.68%
cases:31.98%
controls:5.64%
—
—
cases:34.91%
controls:6.42%
cases:41.51%
controls:33.68%
cases:50.43%
controls:54.71%
94
819
78
900
71
579
101
1140
55
97
117
1622
—
59
110
110
1603
66
543
93
1069
59
621
58
514
pH of Urine
2756-5 [3015736]
-6.6e-04
1.0e-01
2.3e+00
—
1.7e+00
—
-8.1e-01
cases:11.63%
controls:11.63%
cases:6.40%
controls:5.82%
cases:11.63%
controls:1.34%
—
—
cases:4.73%
controls:0.88%
—
—
cases:5.98%
controls:12.51%
20
200
152
1519
11
100
161
1619
20
23
152
1696
—
8
15
161
1698
—
7
142
110
993
Outpatient Hospital
22 [8756]
5.5e-02
3.5e-01
2.1e+00
1.0e+50
1.9e+00
4.2e-01
-3.5e-01
cases:18.02%
controls:17.22%
cases:6.40%
controls:4.60%
cases:4.65%
controls:0.58%
cases:15.12%
controls:0.00%
cases:4.73%
controls:0.76%
cases:5.66%
controls:3.78%
cases:10.26%
controls:13.92%
31
296
141
1423
11
79
161
1640
8
10
164
1709
26
0
146
1719
8
13
161
1700
9
61
150
1551
12
158
105
977
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
-3.7e-01
-5.7e-02
2.3e+00
—
1.6e+00
9.3e-02
-5.4e-01
cases:11.05%
controls:15.24%
cases:7.56%
controls:7.97%
cases:15.70%
controls:1.86%
—
—
cases:6.51%
controls:1.34%
cases:8.18%
controls:7.51%
cases:11.11%
controls:17.71%
19
262
153
1457
13
137
159
1582
27
32
145
1687
—
11
23
158
1690
13
121
146
1491
13
201
104
934
Bacteria identified in Blood by Culture
600-7 [3023368]
-1.3e-01
1.0e+00
—
—
3.9e+00
5.1e-01
-1.2e-01
cases:5.23%
controls:5.93%
cases:3.49%
controls:1.28%
—
—
—
—
cases:14.79%
controls:0.35%
cases:3.77%
controls:2.30%
cases:5.98%
controls:6.70%
9
102
163
1617
6
22
166
1697
—
—
25
6
144
1707
6
37
153
1575
7
76
110
1059
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
-3.9e-01
-7.3e-02
2.3e+00
—
1.5e+00
7.5e-02
-4.0e-01
cases:11.05%
controls:15.47%
cases:7.56%
controls:8.09%
cases:15.70%
controls:1.86%
—
—
cases:5.92%
controls:1.34%
cases:8.18%
controls:7.63%
cases:12.82%
controls:18.06%
19
266
153
1453
13
139
159
1580
27
32
145
1687
—
10
23
159
1690
13
123
146
1489
15
205
102
930
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
-3.5e-01
-1.7e-02
2.3e+00
—
1.5e+00
9.3e-02
-5.5e-01
cases:11.05%
controls:15.01%
cases:7.56%
controls:7.68%
cases:15.70%
controls:1.86%
—
—
cases:5.92%
controls:1.40%
cases:8.18%
controls:7.51%
cases:11.11%
controls:17.80%
19
258
153
1461
13
132
159
1587
27
32
145
1687
—
10
24
159
1689
13
121
146
1491
13
202
104
933
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3.1e-01
1.5e-01
1.9e+00
—
1.7e+00
4.7e-02
-1.3e-01
cases:44.77%
controls:37.17%
cases:23.26%
controls:20.77%
cases:13.37%
controls:2.21%
—
—
cases:14.79%
controls:3.09%
cases:22.01%
controls:21.22%
cases:36.75%
controls:39.82%
77
639
95
1080
40
357
132
1362
23
38
149
1681
—
25
53
144
1660
35
342
124
1270
43
452
74
683
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
6.4e-02
8.3e-02
2.0e+00
1.0e+50
1.6e+00
3.6e-01
-2.8e-01
cases:23.84%
controls:22.69%
cases:10.47%
controls:9.71%
cases:8.14%
controls:1.22%
cases:3.49%
controls:0.00%
cases:7.10%
controls:1.52%
cases:13.84%
controls:10.05%
cases:18.80%
controls:23.44%
41
390
131
1329
18
167
154
1552
14
21
158
1698
6
0
166
1719
12
26
157
1687
22
162
137
1450
22
266
95
869
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
2.2e-01
3.1e-01
3.4e+00
—
1.3e+00
1.3e-01
3.6e-01
cases:26.16%
controls:22.11%
cases:11.05%
controls:8.38%
cases:20.35%
controls:0.87%
—
—
cases:5.33%
controls:1.58%
cases:7.55%
controls:6.70%
cases:23.08%
controls:17.27%
45
380
127
1339
19
144
153
1575
35
15
137
1704
—
9
27
160
1686
12
108
147
1504
27
196
90
939
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.3e-02
-9.0e-02
1.8e+00
—
1.5e+00
6.1e-02
-3.4e-01
cases:29.65%
controls:28.97%
cases:13.95%
controls:15.07%
cases:6.40%
controls:1.16%
—
—
cases:9.47%
controls:2.22%
cases:15.09%
controls:14.33%
cases:21.37%
controls:27.58%
51
498
121
1221
24
259
148
1460
11
20
161
1699
—
16
38
153
1675
24
231
135
1381
25
313
92
822
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
8.4e-01
—
—
3.3e+00
—
—
—
—
cases:2.91%
controls:1.28%
—
—
—
—
cases:7.10%
controls:0.29%
—
—
—
—
—
5
22
167
1697
—
—
12
5
157
1708
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-3.4e-03
-3.9e-02
1.8e+00
—
1.3e+00
2.1e-02
1.6e-01
cases:37.21%
controls:37.29%
cases:16.28%
controls:16.81%
cases:12.79%
controls:2.33%
—
—
cases:7.10%
controls:1.98%
cases:16.35%
controls:16.07%
cases:35.90%
controls:32.33%
64
641
108
1078
28
289
144
1430
22
40
150
1679
—
12
34
157
1679
26
259
133
1353
42
367
75
768
ibuprofen
R02AX02 [1588667]
-3.4e-03
-3.9e-02
1.8e+00
—
1.3e+00
2.1e-02
1.6e-01
cases:37.21%
controls:37.29%
cases:16.28%
controls:16.81%
cases:12.79%
controls:2.33%
—
—
cases:7.10%
controls:1.98%
cases:16.35%
controls:16.07%
cases:35.90%
controls:32.33%
64
641
108
1078
28
289
144
1430
22
40
150
1679
—
12
34
157
1679
26
259
133
1353
42
367
75
768
Bacteria identified in Urine by Culture
630-4 [3026008]
-2.9e-01
8.5e-01
3.1e+00
—
—
4.8e-01
-6.8e-01
cases:4.65%
controls:6.11%
cases:4.65%
controls:2.04%
cases:8.14%
controls:0.41%
—
—
—
—
cases:3.77%
controls:2.36%
cases:4.27%
controls:8.11%
8
105
164
1614
8
35
164
1684
14
7
158
1712
—
—
6
38
153
1574
5
92
112
1043
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
2.1e-01
8.2e-01
3.0e+00
—
—
—
—
cases:8.72%
controls:7.21%
cases:4.65%
controls:2.09%
cases:5.81%
controls:0.29%
—
—
—
—
—
—
—
—
15
124
157
1595
8
36
164
1683
10
5
162
1714
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.51%
controls:0.35%
—
—
—
—
—
—
—
—
11
6
158
1707
—
—
pH of Venous blood
2746-6 [3012544]
—
-1.0e+50
2.9e+00
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.93%
cases:5.23%
controls:0.29%
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
0
16
172
1703
9
5
163
1714
—
—
0
12
159
1600
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
2.7e-02
9.5e-02
2.8e+00
1.0e+50
1.9e+00
1.6e-01
-4.1e-01
cases:9.30%
controls:9.08%
cases:4.65%
controls:4.25%
cases:9.30%
controls:0.64%
cases:5.23%
controls:0.00%
cases:3.55%
controls:0.53%
cases:4.40%
controls:3.78%
cases:7.69%
controls:11.19%
16
156
156
1563
8
73
164
1646
16
11
156
1708
9
0
163
1719
6
9
163
1704
7
61
152
1551
9
127
108
1008
Inpatient Visit
IP [9201]
-1.3e-01
-2.9e-01
—
—
2.7e+00
3.6e-01
-3.9e-01
cases:10.47%
controls:11.75%
cases:2.91%
controls:3.84%
—
—
—
—
cases:6.51%
controls:0.47%
cases:4.40%
controls:3.10%
cases:6.84%
controls:9.78%
18
202
154
1517
5
66
167
1653
—
—
11
8
158
1705
7
50
152
1562
8
111
109
1024
amoxicillin; oral, parenteral
J01CA04 [21602823]
1.2e-01
7.5e-01
2.7e+00
—
—
-3.9e-01
1.6e-01
cases:23.26%
controls:21.12%
cases:10.47%
controls:5.24%
cases:8.72%
controls:0.64%
—
—
—
—
cases:4.40%
controls:6.39%
cases:21.37%
controls:18.77%
40
363
132
1356
18
90
154
1629
15
11
157
1708
—
—
7
103
152
1509
25
213
92
922
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.2e-02
-8.2e-02
1.2e+00
—
1.5e+00
7.2e-02
6.3e-02
cases:40.70%
controls:39.21%
cases:21.51%
controls:22.92%
cases:11.63%
controls:3.96%
—
—
cases:13.02%
controls:3.33%
cases:22.64%
controls:21.40%
cases:41.88%
controls:40.35%
70
674
102
1045
37
394
135
1325
20
68
152
1651
—
22
57
147
1656
36
345
123
1267
49
458
68
677
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
2.1e-01
1.0e+00
—
—
2.6e+00
—
—
cases:3.49%
controls:2.85%
cases:2.91%
controls:1.05%
—
—
—
—
cases:5.33%
controls:0.41%
—
—
—
—
6
49
166
1670
5
18
167
1701
—
—
9
7
160
1706
—
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.9e-01
—
—
—
2.5e+00
8.1e-01
3.5e-01
cases:8.14%
controls:6.81%
—
—
—
—
—
—
cases:3.55%
controls:0.29%
cases:3.14%
controls:1.43%
cases:6.84%
controls:4.93%
14
117
158
1602
—
—
—
6
5
163
1708
5
23
154
1589
8
56
109
1079
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
-1.6e-01
6.3e-02
—
1.0e+50
2.5e+00
1.7e-01
-4.4e-01
cases:6.98%
controls:8.09%
cases:2.91%
controls:2.73%
—
—
cases:4.65%
controls:0.00%
cases:3.55%
controls:0.29%
cases:3.14%
controls:2.67%
cases:5.98%
controls:8.99%
12
139
160
1580
5
47
167
1672
—
8
0
164
1719
6
5
163
1708
5
43
154
1569
7
102
110
1033
Acute upper respiratory infection, unspecified
J06.9 [45562437]
2.2e-01
5.5e-01
2.5e+00
—
—
-1.2e-01
2.7e-01
cases:14.53%
controls:12.04%
cases:8.72%
controls:5.24%
cases:9.30%
controls:0.87%
—
—
—
—
cases:5.03%
controls:5.65%
cases:14.53%
controls:11.45%
25
207
147
1512
15
90
157
1629
16
15
156
1704
—
—
8
91
151
1521
17
130
100
1005
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-7.8e-02
-9.4e-02
1.5e+00
—
2.4e+00
3.9e-01
1.6e-01
cases:11.63%
controls:12.45%
cases:6.40%
controls:6.98%
cases:4.07%
controls:0.93%
—
—
cases:10.06%
controls:1.05%
cases:11.32%
controls:7.94%
cases:14.53%
controls:12.60%
20
214
152
1505
11
120
161
1599
7
16
165
1703
—
17
18
152
1695
18
128
141
1484
17
143
100
992
Osmolality of Urine
2695-5 [3026782]
-3.5e-02
—
2.3e+00
—
—
—
—
cases:5.23%
controls:5.41%
—
—
cases:4.07%
controls:0.41%
—
—
—
—
—
—
—
—
9
93
163
1626
—
7
7
165
1712
—
—
—
—
gabapentin; oral
N02BF01 [955005]
-2.2e-01
1.5e-01
—
—
2.3e+00
8.4e-01
2.4e-01
cases:2.91%
controls:3.61%
cases:2.91%
controls:2.50%
—
—
—
—
cases:7.10%
controls:0.76%
cases:5.03%
controls:2.23%
cases:5.98%
controls:4.76%
5
62
167
1657
5
43
167
1676
—
—
12
13
157
1700
8
36
151
1576
7
54
110
1081
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
3.2e-01
-1.1e-01
2.3e+00
—
2.2e+00
4.3e-01
4.5e-02
cases:15.70%
controls:11.93%
cases:5.81%
controls:6.46%
cases:2.91%
controls:0.29%
—
—
cases:7.69%
controls:0.88%
cases:8.81%
controls:5.89%
cases:15.38%
controls:14.80%
27
205
145
1514
10
111
162
1608
5
5
167
1714
—
13
15
156
1698
14
95
145
1517
18
168
99
967
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
1.3e+00
1.0e+50
1.0e+50
2.2e+00
—
—
—
—
cases:2.91%
controls:0.81%
cases:12.21%
controls:0.00%
cases:7.56%
controls:0.00%
cases:3.55%
controls:0.41%
—
—
—
—
—
5
14
167
1705
21
0
151
1719
13
0
159
1719
6
7
163
1706
—
—
Infectious Disease
44 [38004484]
5.8e-01
—
—
1.0e+50
—
2.2e+00
—
cases:3.49%
controls:1.98%
—
—
—
—
cases:9.88%
controls:0.00%
—
—
cases:6.29%
controls:0.74%
—
—
6
34
166
1685
—
—
17
0
155
1719
—
10
12
149
1600
—
EKG study
11524-6 [3013512]
1.2e-01
2.5e-01
2.2e+00
—
1.9e+00
5.3e-01
-1.5e-01
cases:10.47%
controls:9.42%
cases:6.40%
controls:5.06%
cases:3.49%
controls:0.41%
—
—
cases:3.55%
controls:0.53%
cases:8.18%
controls:4.96%
cases:10.26%
controls:11.72%
18
162
154
1557
11
87
161
1632
6
7
166
1712
—
6
9
163
1704
13
80
146
1532
12
133
105
1002
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
2.3e-02
5.1e-01
—
—
2.1e+00
4.1e-01
6.6e-01
cases:8.14%
controls:7.97%
cases:5.23%
controls:3.20%
—
—
—
—
cases:4.14%
controls:0.53%
cases:3.77%
controls:2.54%
cases:11.11%
controls:6.08%
14
137
158
1582
9
55
163
1664
—
—
7
9
162
1704
6
41
153
1571
13
69
104
1066
Tissue Pathology biopsy report
66121-5 [40768804]
9.0e-01
4.8e-01
-1.0e+50
—
—
1.2e+00
6.4e-01
cases:25.00%
controls:11.98%
cases:6.40%
controls:4.07%
cases:0.00%
controls:0.41%
—
—
—
—
cases:9.43%
controls:3.04%
cases:15.38%
controls:8.72%
43
206
129
1513
11
70
161
1649
0
7
172
1712
—
—
15
49
144
1563
18
99
99
1036
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-2.7e-01
—
2.1e+00
—
1.5e+00
—
—
cases:5.23%
controls:6.75%
—
—
cases:5.23%
controls:0.70%
—
—
cases:3.55%
controls:0.82%
—
—
—
—
9
116
163
1603
—
9
12
163
1707
—
6
14
163
1699
—
—
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
4.2e-01
—
1.0e+50
1.0e+50
—
2.0e+00
1.3e+00
cases:3.49%
controls:2.33%
—
—
cases:18.02%
controls:0.00%
cases:18.02%
controls:0.00%
—
—
cases:5.66%
controls:0.81%
cases:4.27%
controls:1.15%
6
40
166
1679
—
31
0
141
1719
31
0
141
1719
—
9
13
150
1599
5
13
112
1122
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
2.8e-01
—
1.0e+50
1.0e+50
—
2.0e+00
1.8e+00
cases:2.91%
controls:2.21%
—
—
cases:17.44%
controls:0.00%
cases:17.44%
controls:0.00%
—
—
cases:5.03%
controls:0.74%
cases:4.27%
controls:0.70%
5
38
167
1681
—
30
0
142
1719
30
0
142
1719
—
8
12
151
1600
5
8
112
1127
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-6.7e-01
-3.3e-01
1.9e+00
1.0e+50
—
3.0e-01
-3.9e-01
cases:4.65%
controls:8.73%
cases:2.91%
controls:4.01%
cases:6.40%
controls:0.99%
cases:2.91%
controls:0.00%
—
—
cases:5.03%
controls:3.78%
cases:6.84%
controls:9.78%
8
150
164
1569
5
69
167
1650
11
17
161
1702
5
0
167
1719
—
8
61
151
1551
8
111
109
1024
Other specified special examinations
Z01.8 [45581003]
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.66%
controls:1.12%
—
—
—
—
—
—
—
9
18
150
1594
—
cefalexin; oral
J01DB01 [21602870]
5.7e-02
2.5e-01
1.6e+00
—
—
2.3e-01
-2.3e-02
cases:26.16%
controls:25.07%
cases:11.05%
controls:8.78%
cases:4.65%
controls:0.93%
—
—
—
—
cases:9.43%
controls:7.63%
cases:25.64%
controls:26.08%
45
431
127
1288
19
151
153
1568
8
16
164
1703
—
—
15
123
144
1489
30
296
87
839
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
-7.1e-01
-2.9e-01
1.6e+00
—
—
-8.5e-02
-6.7e-01
cases:6.40%
controls:12.22%
cases:3.49%
controls:4.60%
cases:6.98%
controls:1.45%
—
—
—
—
cases:4.40%
controls:4.78%
cases:6.84%
controls:12.51%
11
210
161
1509
6
79
166
1640
12
25
160
1694
—
—
7
77
152
1535
8
142
109
993
Pharmacy visit
OMOP4822462 [581458]
9.2e-02
2.5e-01
9.5e-01
2.1e-01
6.2e-01
3.2e-01
2.4e-01
cases:91.28%
controls:90.52%
cases:86.63%
controls:83.48%
cases:69.77%
controls:47.12%
cases:3.49%
controls:2.85%
cases:63.91%
controls:48.69%
cases:88.05%
controls:84.24%
cases:95.73%
controls:94.63%
157
1556
15
163
149
1435
23
284
120
810
52
909
6
49
166
1670
108
834
61
879
140
1358
19
254
112
1074
5
61
Polysomnography panel
90568-7 [1002224]
1.5e+00
—
—
—
—
—
—
cases:5.23%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
—
—
9
20
163
1699
—
—
—
—
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
-3.6e-02
-2.0e-01
3.4e-02
—
1.4e+00
-1.2e-01
-8.1e-02
cases:20.93%
controls:21.52%
cases:11.05%
controls:13.21%
cases:3.49%
controls:3.37%
—
—
cases:9.47%
controls:2.51%
cases:11.32%
controls:12.59%
cases:19.66%
controls:20.97%
36
370
136
1349
19
227
153
1492
6
58
166
1661
—
16
43
153
1670
18
203
141
1409
23
238
94
897
budesonide; inhalant
R03BA02 [21603285]
7.5e-01
1.1e+00
—
—
-1.0e+50
6.8e-01
6.9e-01
cases:10.47%
controls:5.24%
cases:8.14%
controls:2.73%
—
—
—
—
cases:0.00%
controls:1.05%
cases:5.03%
controls:2.61%
cases:8.55%
controls:4.49%
18
90
154
1629
14
47
158
1672
—
—
0
18
169
1695
8
42
151
1570
10
51
107
1084
Generalized anxiety disorder
F41.1 [45571764]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
7
159
1605
—
Psychiatry
26 [38004469]
-2.4e-01
—
-1.0e+50
—
—
1.8e-01
—
cases:5.81%
controls:7.27%
—
—
cases:0.00%
controls:0.99%
—
—
—
—
cases:3.77%
controls:3.16%
—
—
10
125
162
1594
—
0
17
172
1702
—
—
6
51
153
1561
—
Weakness/tiredness general
A04 [2002000145]
5.8e-01
-1.0e+50
—
—
—
—
—
cases:3.49%
controls:1.98%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
6
34
166
1685
0
12
172
1707
—
—
—
—
—
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
7
172
1712
—
—
—
—
—
0
9
117
1126
cyproterone and estrogen
G03HB01 [21602617]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
172
1711
—
—
—
—
—
—
Telephone prescription or other care instructions
WZB00 [2001310884]
-1.6e-01
—
—
—
—
—
—
cases:4.65%
controls:5.41%
—
—
—
—
—
—
—
—
—
—
—
—
8
93
164
1626
—
—
—
—
—
—
Naevus/mole
S82 [2002001046]
1.2e+00
—
—
—
—
—
—
cases:4.65%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
—
—
8
26
164
1693
—
—
—
—
—
—
Assessment of need for psychiatric treatment
IAA01 [2001304011]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.62%
—
—
—
—
—
0
6
159
1606
0
7
117
1128
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
-3.2e-01
—
—
—
—
—
—
cases:2.91%
controls:3.96%
—
—
—
—
—
—
—
—
—
—
—
—
5
68
167
1651
—
—
—
—
—
—
Shoulder lesions
M75 [45557983]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1607
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:1.32%
0
14
172
1705
—
—
—
—
0
9
159
1603
0
15
117
1120
isosorbide mononitrate; oral
C01DA14 [21600324]
4.4e-01
—
—
—
-1.0e+50
5.0e-01
—
cases:3.49%
controls:2.27%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:3.14%
controls:1.92%
—
—
6
39
166
1680
—
—
—
0
9
169
1704
5
31
154
1581
—
Musculoskeletal sympt/complt other
L29 [2002000648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
10
117
1125
Tick-borne viral encephalitis, unspecified
A84.9 [45571447]
—
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:40.12%
controls:0.00%
cases:19.53%
controls:0.00%
cases:22.01%
controls:0.00%
—
—
—
—
—
69
0
103
1719
33
0
136
1713
35
0
124
1612
—
telmisartan; oral
C09CA07 [21601830]
1.6e+00
—
—
—
—
—
—
cases:2.91%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
167
1709
—
—
—
—
—
—
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
11
159
1601
—
Bone marrow biopsy
XW000 [2001310618]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
9
172
1710
—
—
—
—
—
0
7
117
1128
Lichen rubs planus in the mouth
K13.74 [2000502892]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Acute bronchitis, unspecified
J20.9 [45562445]
7.2e-01
—
—
—
—
—
9.9e-01
cases:4.65%
controls:2.33%
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:2.64%
8
40
164
1679
—
—
—
—
—
8
30
109
1105
Upper respiratory infection acute
R74 [2002000942]
5.4e-01
7.4e-01
—
—
—
—
-1.8e-01
cases:12.21%
controls:7.50%
cases:4.65%
controls:2.27%
—
—
—
—
—
—
—
—
cases:5.98%
controls:7.05%
21
129
151
1590
8
39
164
1680
—
—
—
—
7
80
110
1055
hydrocortisone and antiinfectives
S02CA03 [21605175]
4.4e-01
—
—
—
—
—
—
cases:3.49%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
39
166
1680
—
—
—
—
—
—
Gastroenteritis presumed infection
D73 [2002000371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
172
1706
—
—
—
—
—
—
Scheduled procedure
ZXD10 [2001311387]
3.6e-01
—
—
—
—
—
—
cases:5.81%
controls:4.13%
—
—
—
—
—
—
—
—
—
—
—
—
10
71
162
1648
—
—
—
—
—
—
perindopril and amlodipine
C09BB04 [21601818]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
7
172
1712
0
6
172
1713
—
—
—
—
—
Abdominal X-ray examination without contrast
JN3AA [2001305553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.62%
—
0
5
172
1714
—
—
—
0
5
159
1607
0
7
117
1128
Beta-2-Microglobulin [Mass/volume] in Serum or Plasma
1952-1 [3013201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
5.5e-01
—
—
—
—
—
—
cases:3.49%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
35
166
1684
—
—
—
—
—
—
electrolytes with carbohydrates
B05BB02 [21601162]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Presence of orthopaedic joint implants
Z96.6 [45600385]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.97%
0
11
172
1708
—
—
—
—
0
7
159
1605
0
11
117
1124
esomeprazole; oral, parenteral
A02BC05 [21600100]
2.8e-01
-2.9e-01
—
—
—
-1.5e-01
-4.2e-01
cases:10.47%
controls:8.14%
cases:3.49%
controls:4.60%
—
—
—
—
—
—
cases:3.77%
controls:4.34%
cases:5.13%
controls:7.58%
18
140
154
1579
6
79
166
1640
—
—
—
6
70
153
1542
6
86
111
1049
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
mirabegron; oral
G04BD12 [43534790]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
0
10
169
1703
—
—
Senile nuclear cataract
H25.1 [45581628]
2.1e-01
—
—
—
—
—
—
cases:4.07%
controls:3.32%
—
—
—
—
—
—
—
—
—
—
—
—
7
57
165
1662
—
—
—
—
—
—
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
9
172
1710
—
—
—
—
0
6
159
1606
—
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1710
—
—
—
—
—
—
Examination of peripheral nervous system
SPAT1054 [2001700155]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.65%
controls:0.00%
—
—
—
—
—
—
—
—
—
8
0
164
1719
—
—
—
Elevated level of transaminase and lactic acid dehydrogenase
274774002 [436238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Arthroplasty of interphalangeal tarsal joint(s)
NHG77 [2001308321]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
3.4e-01
3.2e-01
—
—
-1.0e+50
1.5e-02
1.6e-01
cases:22.67%
controls:17.22%
cases:8.14%
controls:6.05%
—
—
—
—
cases:0.00%
controls:1.28%
cases:5.66%
controls:5.58%
cases:17.09%
controls:14.89%
39
296
133
1423
14
104
158
1615
—
—
0
22
169
1691
9
90
150
1522
20
169
97
966
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
6
172
1713
—
—
—
—
—
0
5
117
1130
Mouth breathing
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
172
1702
—
—
—
—
—
—
Destruction of lesion of skin, site unspecified
QXA25 [2001310041]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
8
172
1711
—
—
—
—
—
0
5
117
1130
dexamethasone
D07AB19 [21602116]
—
-1.0e+50
—
—
—
-1.0e+50
8.1e-01
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
cases:4.27%
controls:1.94%
—
0
13
172
1706
—
—
—
0
12
159
1600
5
22
112
1113
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
10
172
1709
—
—
—
—
—
Cervicobrachial syndrome
M53.1 [45567577]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
Varicella zoster virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay
69930-6 [42868421]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:6.98%
controls:0.00%
cases:2.96%
controls:0.00%
—
—
—
—
—
—
—
12
0
160
1719
5
0
164
1713
—
—
fluorometholone
S01BA07 [21603624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1710
—
—
—
—
—
—
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
3.1e-01
—
—
—
1.0e+50
—
—
cases:2.91%
controls:2.15%
—
—
—
—
—
—
cases:3.55%
controls:0.00%
—
—
—
—
5
37
167
1682
—
—
—
6
0
163
1713
—
—
Haemoptysis
R04.2 [45577777]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Occupational Medicine Clinic/Center
261QX0100X [38004267]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:2.96%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
164
1713
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:3.00%
—
—
—
—
—
—
6
34
111
1101
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.87%
—
—
—
—
cases:0.00%
controls:0.47%
cases:0.00%
controls:0.81%
cases:0.00%
controls:1.15%
—
0
15
172
1704
—
—
0
8
169
1705
0
13
159
1599
0
13
117
1122
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
117
1128
Psychiatric treatment plan, extended/prolonged
ICB02 [2001304099]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
3.7e-01
1.1e+00
—
—
—
—
-1.0e+50
cases:5.23%
controls:3.66%
cases:3.49%
controls:1.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.38%
9
63
163
1656
6
21
166
1698
—
—
—
—
0
27
117
1108
Skin infection other
S76 [2002001040]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
172
1709
—
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
1.5e-01
—
-1.0e+50
—
-1.0e+50
—
-1.0e+50
cases:3.49%
controls:3.03%
—
—
cases:0.00%
controls:0.81%
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:2.47%
6
52
166
1667
—
0
14
172
1705
—
0
5
169
1708
—
0
28
117
1107
Chronic ischaemic heart disease
I25 [45581765]
1.2e+00
—
—
—
—
—
—
cases:2.91%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
167
1703
—
—
—
—
—
—
chlorhexidine; oral
R02AA05 [21603221]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Weight gain
T07 [2002001070]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
liraglutide; parenteral
A10BJ02 [1123630]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
172
1708
—
—
—
—
—
—
ivermectin; oral
P02CF01 [21604957]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
117
1129
chloramphenicol; ointment
D06AX02 [21602063]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
9
172
1710
—
—
—
0
6
159
1606
—
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
97097-0 [36033641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
172
1711
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
0
5
172
1714
—
—
—
—
0
16
117
1119
Ankylosing spondylitis
M45 [45591841]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
6
172
1713
—
—
—
—
0
7
159
1605
—
General health counselling
SPAT1312 [2001700413]
-1.5e-01
—
—
—
—
—
2.4e-01
cases:6.40%
controls:7.33%
—
—
—
—
—
—
—
—
—
—
cases:5.98%
controls:4.76%
11
126
161
1593
—
—
—
—
—
7
54
110
1081
Preventive oral health care, short
SCA01 [2001310302]
4.8e-01
—
—
—
—
-1.0e+50
—
cases:9.30%
controls:5.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
16
103
156
1616
—
—
—
—
0
19
159
1593
—
Scanning laser polarimetry
392005004 [4194118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Depressive episode
F32 [45595904]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Risk factor cardiovascular disease
K22 [2002000551]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
Uroflowmetry
44856007 [4261340]
5.5e-01
—
—
—
—
—
—
cases:3.49%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
35
166
1684
—
—
—
—
—
—
folic acid
V04CX02 [715877]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
0
8
172
1711
—
0
5
169
1708
—
—
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
2.7e-01
—
—
—
—
—
—
cases:6.40%
controls:4.94%
—
—
—
—
—
—
—
—
—
—
—
—
11
85
161
1634
—
—
—
—
—
—
Hypertensive heart disease without (congestive) heart failure
I11.9 [45576863]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
8
159
1604
—
Giving the first information
R2110 [2001310194]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
172
1705
—
—
—
—
—
—
Other minor procedure in surgery of teeth, jaws, mouth and pharynx
TEW99 [2001302349]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Plastic And Reconstructive Surgery
24 [38004467]
2.9e-01
—
-1.0e+50
—
—
—
1.1e-02
cases:5.23%
controls:3.96%
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:4.27%
controls:4.23%
9
68
163
1651
—
0
5
172
1714
—
—
—
5
48
112
1087
Nursing episode
950 [44777714]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
14
172
1705
—
—
—
—
—
Nutrition survey
SPAT1139 [2001700240]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
fenoterol and ipratropium bromide
R03AL01 [43534843]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.44%
0
11
172
1708
0
9
172
1710
—
—
—
0
7
159
1605
0
5
117
1130
Bacteria [Presence] in Cerebral spinal fluid by Light microscopy
41602-4 [3033386]
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:6.98%
controls:0.00%
cases:15.70%
controls:0.00%
cases:8.28%
controls:0.00%
—
—
—
—
—
—
12
0
160
1719
27
0
145
1719
14
0
155
1713
—
—
Specialised imaging for glaucoma
CS5Z4 [2001301479]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
6
117
1129
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
172
1701
—
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
6.0e-01
—
—
—
—
-1.0e+50
—
cases:4.07%
controls:2.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
7
39
165
1680
—
—
—
—
0
12
159
1600
—
potassium chloride; oral
A12BA01 [21600877]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.51%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
0
26
172
1693
0
15
172
1704
—
—
—
—
—
Emergency Room - Hospital
23 [8870]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Mastodynia
N64.4 [45539060]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
10
172
1709
—
—
—
—
—
0
5
117
1130
Otolaryngology
4 [38004449]
3.2e-02
-5.0e-01
—
—
—
2.0e-01
-6.9e-02
cases:12.21%
controls:11.87%
cases:2.91%
controls:4.71%
—
—
—
—
—
—
cases:5.03%
controls:4.16%
cases:11.11%
controls:11.81%
21
204
151
1515
5
81
167
1638
—
—
—
8
67
151
1545
13
134
104
1001
Bacterial infection, unspecified
A49.9 [45590816]
—
-1.0e+50
1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.58%
cases:3.49%
controls:0.00%
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.15%
—
0
10
172
1709
6
0
166
1719
—
—
0
6
159
1606
0
13
117
1122
Application of cast or individual aid
SPAT1210 [2001700311]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1710
—
—
—
—
—
—
Differential panel - Synovial fluid
29582-4 [3021788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Urinary tract ultrasound examination
KH1AE [2001306329]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
11
172
1708
—
—
—
—
—
0
9
117
1126
triptorelin; parenteral
L02AE04 [21603827]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Other disorders of vitreous body
H43.8 [45533329]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
—
-1.0e+50
—
1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
cases:8.72%
controls:0.00%
—
—
—
—
—
—
—
0
5
172
1714
—
15
0
157
1719
—
—
—
pimecrolimus
D11AH02 [21602339]
1.5e+00
—
—
—
—
—
-1.0e+50
cases:2.91%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
5
11
167
1708
—
—
—
—
—
0
8
117
1127
hydrocortisone and antiinfectives
S03CA04 [21605208]
4.4e-01
—
—
—
—
—
—
cases:3.49%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
39
166
1680
—
—
—
—
—
—
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
-1.0e+50
—
1.0e+50
1.0e+50
—
—
—
cases:0.00%
controls:0.35%
—
—
cases:2.91%
controls:0.00%
cases:8.14%
controls:0.00%
—
—
—
—
—
—
0
6
172
1713
—
5
0
167
1719
14
0
158
1719
—
—
—
Visual disturbance, unspecified
H53.9 [45557475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
-1.4e-01
—
—
—
—
—
—
cases:4.07%
controls:4.65%
—
—
—
—
—
—
—
—
—
—
—
—
7
80
165
1639
—
—
—
—
—
—
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
172
1706
—
—
—
—
—
—
etanercept; parenteral
L04AB01 [21603908]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Lithium [Moles/volume] in Serum or Plasma
14334-7 [3024666]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Herpes simplex virus Ab [Presence] in Serum
22339-6 [3028679]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:2.91%
controls:0.00%
cases:2.96%
controls:0.00%
—
—
—
—
—
—
—
5
0
167
1719
5
0
164
1713
—
—
Other specified counselling
Z71.8 [45581061]
4.1e-01
3.9e-01
—
—
—
2.3e-01
2.3e-02
cases:9.30%
controls:6.40%
cases:5.23%
controls:3.61%
—
—
—
—
—
—
cases:5.03%
controls:4.03%
cases:8.55%
controls:8.37%
16
110
156
1609
9
62
163
1657
—
—
—
8
65
151
1547
10
95
107
1040
indometacin
C01EB03 [21600365]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
8
172
1711
—
—
—
—
0
5
159
1607
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
0
13
172
1706
—
—
—
—
—
Kuhnt-Junius degeneration
H35.30 [2000502314]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
9
172
1710
—
—
—
—
—
Gastro-oesophageal reflux disease
K21 [45586708]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.79%
—
0
10
172
1709
—
—
—
0
7
159
1605
0
9
117
1126
Precision impression for denture
SPA47 [2001310477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
10
117
1125
insulin (human); parenteral
A10AD01 [21600729]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
0
7
172
1712
—
—
—
—
Recurrent depression, moderate episode of somatic syndrome
F33.11 [2000501985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
8.0e-01
8.8e-01
—
—
—
1.1e+00
—
cases:4.65%
controls:2.15%
cases:2.91%
controls:1.22%
—
—
—
—
—
—
cases:3.14%
controls:1.05%
—
—
8
37
164
1682
5
21
167
1698
—
—
—
5
17
154
1595
—
Endocrinology
46 [38004485]
3.3e-01
4.2e-01
—
—
—
6.3e-01
—
cases:5.81%
controls:4.25%
cases:2.91%
controls:1.92%
—
—
—
—
—
—
cases:3.77%
controls:2.05%
—
—
10
73
162
1646
5
33
167
1686
—
—
—
6
33
153
1579
—
Ganglion
M67.4 [45582222]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
12
117
1123
Helicobacter pylori Ab [Units/volume] in Serum
7900-4 [3017895]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
Migraine without aura [common migraine]
G43.0 [45600784]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
Asthma
J45 [45596282]
7.2e-01
—
—
—
—
—
—
cases:4.65%
controls:2.33%
—
—
—
—
—
—
—
—
—
—
—
—
8
40
164
1679
—
—
—
—
—
—
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.00%
—
—
—
—
—
—
—
—
6
0
163
1713
—
—
Intensive care
WX872 [2001310844]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
7
172
1712
—
—
—
—
—
0
6
117
1129
Viral meningitis, unspecified
A87.9 [45600441]
—
—
1.0e+50
1.0e+50
—
1.0e+50
—
—
—
—
—
cases:6.98%
controls:0.00%
cases:5.23%
controls:0.00%
—
—
cases:3.77%
controls:0.00%
—
—
—
—
12
0
160
1719
9
0
163
1719
—
6
0
153
1612
—
Intravenous
ZX120 [2001311495]
—
-1.0e+50
—
1.0e+50
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.41%
—
—
cases:2.91%
controls:0.00%
—
—
—
—
cases:0.00%
controls:0.62%
—
0
7
172
1712
—
5
0
167
1719
—
—
0
7
117
1128
prazosin; oral
C02CA01 [21600411]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1607
—
fusidic acid
S01AA13 [21603564]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
Sprain and strain involving (fibular)(tibial) collateral ligament of knee
S83.4 [45550630]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
5
172
1714
—
—
—
—
—
0
7
117
1128
Sedation and analgesia
WX002 [2001310758]
-8.0e-02
—
—
—
—
-1.0e+50
—
cases:2.91%
controls:3.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
5
54
167
1665
—
—
—
—
0
7
159
1605
—
Obesity
E66 [45547648]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
0
8
172
1711
—
—
—
—
0
5
117
1130
Heartburn
D03 [2002000302]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Home Visit
OMOP4822459 [581476]
-6.4e-01
—
—
—
1.5e+00
-6.5e-02
-4.9e-02
cases:3.49%
controls:6.40%
—
—
—
—
—
—
cases:4.73%
controls:1.11%
cases:3.14%
controls:3.35%
cases:5.13%
controls:5.37%
6
110
166
1609
—
—
—
8
19
161
1694
5
54
154
1558
6
61
111
1074
Fixed dental crown
SPC01 [2001310505]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
9.0e-02
8.7e-01
—
—
—
2.9e-01
-1.1e-01
cases:6.40%
controls:5.88%
cases:4.07%
controls:1.75%
—
—
—
—
—
—
cases:3.77%
controls:2.85%
cases:5.98%
controls:6.61%
11
101
161
1618
7
30
165
1689
—
—
—
6
46
153
1566
7
75
110
1060
cough suppressants and mucolytics
R05FB01 [21603441]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
9
172
1710
—
—
—
—
0
6
159
1606
—
Removal of sutures from oral mucosa
SXB00 [2001310580]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
Polymyalgia rheumatica
M35.3 [45533830]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.44%
0
12
172
1707
0
7
172
1712
—
—
—
0
6
159
1606
0
5
117
1130
Menopausal and female climacteric states
N95.1 [45548683]
5.2e-01
-1.0e+50
—
—
—
—
—
cases:2.91%
controls:1.75%
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
5
30
167
1689
0
21
172
1698
—
—
—
—
—
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:4.07%
controls:0.00%
cases:5.81%
controls:0.00%
—
—
—
—
—
—
—
—
7
0
165
1719
10
0
162
1719
—
—
—
Dermatitis, unspecified
L30.9 [45572271]
-2.4e-01
—
—
—
—
—
—
cases:2.91%
controls:3.66%
—
—
—
—
—
—
—
—
—
—
—
—
5
63
167
1656
—
—
—
—
—
—
polymyxin B
S02AA11 [21605157]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
117
1128
Retention of urine
R33 [45587507]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.05%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
0
18
172
1701
0
5
172
1714
—
—
—
—
0
15
117
1120
melatonin; oral
N05CH01 [21604659]
-1.4e-01
—
—
—
—
—
2.9e-01
cases:4.07%
controls:4.65%
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:3.88%
7
80
165
1639
—
—
—
—
—
6
44
111
1091
Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
21598-8 [3016894]
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:6.40%
controls:0.00%
cases:13.95%
controls:0.00%
cases:7.10%
controls:0.00%
—
—
—
—
—
—
11
0
161
1719
24
0
148
1719
12
0
157
1713
—
—
Gastrointestinal haemorrhage, unspecified
K92.2 [45533625]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Wrist and hand MRI examination with high intensity magnet
ND1BG [2001307586]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Fear of hypertension
K25 [2002000553]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Presbyacusis
H84 [2002000539]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1607
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
0
27
172
1692
—
—
—
—
0
12
159
1600
—
Chronic maxillary sinusitis
J32.0 [45586667]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
0
11
172
1708
0
7
172
1712
—
—
—
—
—
MRI examination of bile and pancreas ducts with high intesity magnet
JL5BG [2001305383]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1712
—
—
—
—
—
—
Fracture of other metacarpal bone
S62.3 [45554785]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
Other minor procedure in surgery of ear, nose and larynx
TDW99 [2001301879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
carbimazole; oral
H03BB01 [21602765]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
7
172
1712
0
5
172
1714
—
—
—
—
0
7
117
1128
Thoracic aortic aneurysm, without mention of rupture
I71.2 [45601082]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
7
172
1712
—
—
—
—
0
5
159
1607
—
Overnight pulse oximetry
252568001 [4091874]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1712
—
—
—
—
—
—
norethisterone; oral
G03DC02 [21602553]
3.6e-01
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:2.91%
controls:2.04%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.97%
5
35
167
1684
0
7
172
1712
—
—
—
0
6
159
1606
0
11
117
1124
androstanolone
G03BB02 [21602513]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
10
172
1709
—
—
—
—
0
7
159
1605
—
Erythrocytes [#/volume] in Synovial fluid
26458-0 [3010144]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
zopiclone; oral
N05CF01 [21604654]
1.8e-01
1.9e-01
—
—
8.5e-01
3.9e-01
1.7e-01
cases:8.72%
controls:7.39%
cases:5.23%
controls:4.36%
—
—
—
—
cases:2.96%
controls:1.28%
cases:6.29%
controls:4.34%
cases:8.55%
controls:7.31%
15
127
157
1592
9
75
163
1644
—
—
5
22
164
1691
10
70
149
1542
10
83
107
1052
valsartan and amlodipine
C09DB01 [21601842]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
Amphetamines [Presence] in Urine
3349-8 [3027944]
1.1e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:2.91%
controls:0.99%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
5
17
167
1702
0
9
172
1710
—
—
—
0
12
159
1600
—
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
S83.5 [45608523]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
0
9
172
1710
—
—
—
—
0
10
117
1125
Anxiety disorder, unspecified
F41.9 [45542849]
9.0e-01
—
—
—
—
—
—
cases:3.49%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
25
166
1694
—
—
—
—
—
—
fludrocortisone and antiinfectives
S02CA07 [21605179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
7
117
1128
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
172
1712
—
—
—
—
—
—
Visual field defects
H53.4 [45557469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
—
—
—
—
1.0e+50
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.00%
—
—
cases:0.00%
controls:0.53%
—
—
—
—
6
0
163
1713
—
0
6
117
1129
Fall on same level involving ice and snow
W00 [45756242]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
9
172
1710
—
—
—
0
6
159
1606
—
temazepam; oral
N05CD07 [21604642]
-4.1e-02
—
—
—
—
3.0e-01
—
cases:2.91%
controls:3.03%
—
—
—
—
—
—
—
—
cases:3.14%
controls:2.36%
—
—
5
52
167
1667
—
—
—
—
5
38
154
1574
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
7.7e-01
1.2e+00
—
—
—
—
3.1e-01
cases:4.65%
controls:2.21%
cases:2.91%
controls:0.93%
—
—
—
—
—
—
—
—
cases:4.27%
controls:3.17%
8
38
164
1681
5
16
167
1703
—
—
—
—
5
36
112
1099
Other bursitis of hip
M70.7 [45606305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
172
1713
—
—
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
6.1e-01
—
—
—
—
—
—
cases:3.49%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
6
33
166
1686
—
—
—
—
—
—
indometacin; oral, parenteral, rectal
M01AB01 [21603941]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
8
172
1711
—
—
—
—
0
6
159
1606
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
9.5e-02
3.6e-02
—
—
1.3e+00
3.9e-01
1.6e-01
cases:13.95%
controls:12.86%
cases:6.98%
controls:6.75%
—
—
—
—
cases:2.96%
controls:0.82%
cases:10.06%
controls:7.07%
cases:17.95%
controls:15.68%
24
221
148
1498
12
116
160
1603
—
—
5
14
164
1699
16
114
143
1498
21
178
96
957
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
5
117
1130
Contusion of finger(s) without damage to nail
S60.0 [45535417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
—
—
—
—
1.9e+00
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:2.96%
controls:0.47%
—
—
cases:0.00%
controls:2.73%
—
—
—
—
5
8
164
1705
—
0
31
117
1104
Other change in the oral mucosa
K13.78 [2000502893]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
5
172
1714
—
—
—
—
—
0
7
117
1128
Ankle X-ray examination without contrast
NH1AA [2001308235]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
6
172
1713
—
—
—
—
0
5
159
1607
—
Preretinal fibrosis of the macula
H35.38 [2000502318]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
7
172
1712
0
7
172
1712
—
—
—
0
8
159
1604
—
Plugged feeling ear
H13 [2002000480]
4.5e-01
—
—
—
—
—
—
cases:4.65%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
8
52
164
1667
—
—
—
—
—
—
European tick borne encephalitis virus IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay
69927-2 [42868418]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:9.88%
controls:0.00%
cases:4.14%
controls:0.00%
—
—
—
—
—
—
—
17
0
155
1719
7
0
162
1713
—
—
Demanding operative extraction of tooth
EBA12 [2001301926]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
7
172
1712
—
—
—
—
—
0
6
117
1129
Chronic laryngitis
J37.0 [45601128]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
172
1714
—
—
—
—
—
—
Vertigo/dizziness
N17 [2002000728]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
27
172
1692
0
8
172
1711
—
—
—
—
—
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.99%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
17
172
1702
0
7
172
1712
—
—
—
0
8
159
1604
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
70
18
63.00
119.65
1.1
1.5
—
—
—
0
0
80
33
42.84
119.64
1.1
1.3
—
—
—
0
0
71
42
27.26
90.85
1.1
1.3
75.89
3115.97
e6/l
0.54
35
31
69
41
26.67
87.95
1.1
1.2
88.50
5.62
e6/l
2.83
32
29
101
121
17.74
87.39
3.4
2.6
20.81
12.69
au/ml
0.65
20
12
97
110
17.96
86.94
1.8
1.3
60.49
24.61
au/ml
—
12
9
54
22
34.64
79.42
1.1
1.5
—
—
—
0
0
41
17
30.94
59.23
1.1
1.1
—
—
—
0
0
118
433
6.01
31.19
3.4
4.8
—
—
—
0
0
29
10
34.21
22.68
1.2
1.4
2.15
1.87
mmol/l
—
29
10
104
562
3.01
11.93
5.9
6.3
—
—
—
0
0
125
790
2.91
10.03
6.5
6.9
8.82
8.69
%
0.18
119
745
125
793
2.89
9.91
6.4
6.8
58.35
57.74
%
0.18
120
758
124
788
2.84
9.71
6.5
6.8
0.56
0.71
%
2.41
118
734
79
403
2.71
9.58
3.6
4.4
87.27
92.50
%
1.32
79
398
14
10
15.05
8.85
1.1
1.0
—
—
—
0
0
122
792
2.68
8.77
6.5
6.8
2.17
2.88
%
1.84
116
745
59
272
2.74
8.58
2.3
3.2
4.21
1.84
e6/l
0.49
20
123
16
19
9.12
8.00
1.0
1.2
—
—
—
0
0
125
859
2.49
7.37
6.7
6.9
0.04
0.04
e9/l
1.41
106
722
124
856
2.44
7.13
6.7
6.9
0.58
0.58
e9/l
0.10
105
723
126
881
2.43
6.96
6.9
7.3
0.13
0.20
e9/l
6.14
111
763
125
871
2.42
6.96
6.7
6.9
1.72
1.78
e9/l
0.22
109
759
17
30
6.14
6.64
1.0
1.3
232.36
247.45
u/ml
0.08
11
11
59
305
2.39
6.53
1.6
1.9
—
—
—
0
0
81
482
2.24
6.42
2.7
3.2
0.29
0.43
e6/l
0.55
49
344
19
52
3.97
6.39
1.2
1.4
—
—
—
0
0
89
553
2.21
6.32
2.8
3.4
34.06
171.28
e6/l
0.60
61
417
108
726
2.22
6.28
5.3
6.6
1.20
1.22
mmol/l
2.40
96
677
96
617
2.19
6.23
2.3
2.2
—
—
—
0
0
97
628
2.18
6.16
3.7
4.0
23.18
86.77
e6/l
1.37
64
437
155
1227
2.90
6.05
8.2
8.7
73.23
81.11
u/l
1.63
150
1168
129
949
2.27
5.77
8.8
11.0
4.50
4.10
e9/l
0.72
110
817
121
881
2.14
5.37
5.4
7.1
10.62
11.37
umol/l
0.54
115
840
111
794
2.04
5.03
5.7
7.5
1.21
1.21
mmol/l
0.59
98
694
30
134
2.49
4.46
3.4
4.8
7.40
7.36
ph
0.87
18
97
7
6
12.06
4.31
1.1
1.0
1200.86
1825.67
miu/ml
—
7
6
13
31
4.44
4.10
1.0
1.4
186.00
151.76
au/ml
—
5
11
172
1551
3.45
3.98
19.3
16.1
21.41
23.48
mg/l
0.44
164
1282
91
665
1.75
3.34
2.2
2.1
94.54
95.54
pmol/l
0.06
46
334
50
308
1.86
3.24
3.5
4.0
82.79
193.68
ng/l
0.51
38
237
21
95
2.37
3.04
1.0
1.1
—
—
—
0
0
24
116
2.23
2.99
1.5
2.4
—
—
—
0
0
10
27
3.86
2.93
1.2
1.1
—
—
—
0
0
10
27
3.86
2.93
1.2
1.1
—
—
—
0
0
10
29
3.59
2.74
1.1
1.0
—
—
—
0
0
67
477
1.64
2.55
2.4
2.7
—
0.22
—
0
9
10
32
3.25
2.48
1.1
1.1
—
—
—
0
0
54
366
1.68
2.47
1.3
1.4
2.02
2.63
g/l
1.64
27
213
0
66
0.00
2.46
0.0
3.8
—
1.49
—
0
59
26
142
1.97
2.39
1.5
1.7
—
—
—
0
0
24
128
2.01
2.35
1.5
1.8
6.56
6.05
ph
—
8
87
8
24
3.44
2.21
1.0
1.1
—
—
—
0
0
65
474
1.58
2.19
1.7
1.7
18.76
21.88
nmol/l
1.28
52
402
59
422
1.59
2.15
2.5
3.0
342.06
346.16
umol/l
0.11
51
378
8
25
3.30
2.12
1.4
1.1
—
—
—
0
0
89
701
1.53
2.11
3.3
4.9
35.11
35.88
g/l
0.70
84
666
86
675
1.52
2.06
2.8
3.4
6.17
6.20
ph
0.05
35
378
7
21
3.42
1.98
1.3
1.3
—
—
—
0
0
29
175
1.78
1.98
7.9
8.0
7.42
7.42
ph
0.03
13
101
67
509
1.50
1.82
2.5
4.3
7.41
7.40
ph
1.38
46
372
28
172
1.74
1.81
8.2
8.2
2.01
0.91
mmol/l
0.95
22
149
19
103
1.94
1.80
10.5
7.8
25.46
24.70
mmol/l
0.52
19
103
49
657
0.65
1.78
2.6
3.2
—
—
—
0
0
17
89
2.01
1.77
1.4
3.3
0.52
0.60
%
0.75
17
89
49
353
1.53
1.70
1.7
1.7
0.80
1.32
mg/l
1.44
35
285
67
516
1.48
1.69
7.1
6.5
—
—
—
0
0
8
31
2.65
1.68
1.3
1.6
—
—
—
0
0
0
43
0.00
1.54
0.0
13.2
—
—
—
0
0
36
247
1.57
1.54
1.3
1.4
120.00
612.88
titre
—
7
59
66
515
1.44
1.53
2.1
2.6
52.72
75.40
u/l
1.13
60
483
6
21
2.92
1.52
1.2
1.3
26.17
25.12
ng/l
—
6
21
86
707
1.41
1.49
11.0
12.5
1.20
1.20
inr
0.01
67
590
11
52
2.19
1.47
1.4
1.2
—
—
—
0
0
100
848
1.40
1.43
3.1
3.8
171.00
9.44
estimate
—
9
199
16
89
1.88
1.42
1.4
3.3
0.87
1.18
%
1.55
16
89
99
840
1.40
1.40
3.1
3.7
0.00
0.00
estimate
—
9
196
101
861
1.39
1.38
3.1
3.8
0.00
0.00
estimate
—
9
176
15
83
1.88
1.36
1.4
1.2
—
—
—
0
0
6
134
0.43
1.34
3.5
3.6
—
—
—
0
0
6
134
0.43
1.34
3.8
4.4
1.21
1.22
mmol/l
—
6
119
155
1433
1.59
1.33
5.3
5.3
1.67
1.94
mu/l
2.53
142
1323
6
24
2.55
1.31
1.5
1.7
—
—
—
0
0
6
24
2.55
1.31
2.0
1.7
—
—
—
0
0
11
55
2.07
1.30
1.1
1.1
—
—
—
0
0
134
1206
1.43
1.29
3.7
4.2
14.78
14.80
pmol/l
0.04
119
1106
127
1133
1.41
1.28
3.1
3.4
50.77
48.33
u/l
0.12
122
1071
36
258
1.49
1.27
1.6
1.6
—
—
—
0
0
86
722
1.37
1.26
3.0
3.1
139.31
122.92
ug/l
0.28
76
679
30
207
1.54
1.26
1.5
1.6
—
—
—
0
0
25
166
1.59
1.23
1.6
4.3
7.38
7.38
ph
0.04
11
94
5
19
2.68
1.22
3.2
5.0
2.36
3.53
nmol/l
—
5
19
22
142
1.63
1.21
1.2
1.2
—
—
—
0
0
90
766
1.35
1.19
9.3
12.1
0.00
0.00
e9/l
0.01
67
617
74
617
1.34
1.10
3.1
3.8
60.44
35.46
ng/l
0.27
55
443
23
155
1.55
1.07
9.1
8.8
—
—
—
0
0
17
106
1.67
1.07
12.2
10.7
95.61
93.65
%
1.76
17
106
62
507
1.34
1.04
2.4
2.3
—
—
—
0
0
9
47
1.96
1.04
1.0
1.1
—
—
—
0
0
12
68
1.82
1.03
1.6
1.7
—
—
—
0
0
12
69
1.79
0.99
2.5
2.4
—
—
—
0
0
28
377
0.70
0.97
4.9
5.8
—
—
—
0
0
11
62
1.82
0.96
1.2
1.5
—
—
—
0
0
21
143
1.53
0.95
1.8
2.7
0.23
0.22
g/l
0.31
21
133
14
87
1.66
0.90
1.1
1.7
—
5.77
—
0
20
6
111
0.52
0.86
1.5
1.2
229.17
350.55
u/ml
—
6
101
11
65
1.74
0.84
1.2
1.5
—
—
—
0
0
6
32
1.90
0.82
1.0
1.7
—
—
—
0
0
31
236
1.38
0.81
8.1
7.3
103.26
104.54
mmol/l
1.03
31
236
26
192
1.41
0.81
1.7
1.6
—
—
—
0
0
11
66
1.71
0.80
1.2
1.5
—
—
—
0
0
21
149
1.46
0.80
2.7
3.5
90.99
74.77
e9/l
0.73
13
106
0
24
0.00
0.80
0.0
3.1
—
—
—
0
0
0
25
0.00
0.79
0.0
1.8
—
9.68
—
0
25
20
141
1.47
0.78
1.6
1.5
—
—
—
0
0
11
67
1.68
0.77
1.2
1.5
—
—
—
0
0
11
67
1.68
0.77
1.2
1.5
—
—
—
0
0
54
636
0.78
0.75
2.8
3.6
0.00
0.00
estimate
—
7
168
174
1693
1.83
0.75
28.4
24.3
90.79
91.11
fl
0.37
174
1682
174
1694
1.81
0.75
28.4
24.3
30.30
30.39
pg
0.25
174
1683
174
1694
1.81
0.75
29.6
24.8
39.80
40.79
%
1.61
174
1682
5
24
2.11
0.75
1.4
1.6
—
—
—
0
0
53
445
1.27
0.71
2.2
3.0
—
—
—
0
0
48
399
1.28
0.70
2.3
2.2
2.97
2.72
mg/l
0.19
38
352
42
345
1.28
0.67
3.8
3.2
0.46
0.73
ug/l
3.50
23
219
19
138
1.42
0.65
1.3
1.4
—
—
—
0
0
27
209
1.34
0.65
1.4
1.7
—
—
—
0
0
5
29
1.74
0.64
1.4
1.1
—
—
—
0
0
174
1696
1.78
0.64
28.8
24.5
134.16
136.52
g/l
1.70
174
1683
8
52
1.56
0.60
1.3
1.6
—
6.40
—
0
11
64
561
1.22
0.58
6.8
5.3
2.93
1.82
ug/l
0.50
55
505
18
133
1.39
0.57
1.8
1.9
3.52
3.60
mmol/l
0.12
11
98
48
409
1.24
0.57
1.3
1.3
0.57
1.22
u/ml
—
9
119
28
226
1.28
0.52
1.1
1.2
—
—
—
0
0
18
136
1.36
0.51
1.6
2.9
0.30
0.29
e6/l
0.03
18
131
9
65
1.40
0.51
1.0
1.2
—
—
—
0
0
34
283
1.25
0.50
1.3
1.3
1.47
5.39
u/ml
—
10
114
166
1612
1.38
0.50
13.8
13.6
—
—
—
0
0
155
1495
1.26
0.46
4.9
4.3
1.23
1.31
mmol/l
1.02
138
1388
41
473
0.83
0.45
2.0
3.0
0.00
0.00
estimate
—
7
158
40
462
0.83
0.45
3.6
4.1
0.00
0.00
estimate
—
8
180
37
315
1.22
0.45
1.4
1.3
60.57
26.36
iu/ml
—
7
102
5
31
1.63
0.43
2.4
3.4
15.00
43.13
u/ml
—
5
31
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
18.1
—
1714.07
—
0
15
128
1333
0.86
0.35
25.6
20.1
13.55
13.57
%
0.06
128
1327
23
192
1.23
0.34
1.7
1.4
—
—
—
0
0
59
538
1.14
0.33
3.7
3.6
2.33
2.35
mmol/l
0.49
48
494
15
186
0.79
0.33
1.4
1.6
—
—
—
0
0
7
54
1.31
0.31
1.3
1.2
—
101.25
—
0
8
23
195
1.21
0.30
1.2
1.4
—
—
—
0
0
48
436
1.14
0.28
1.3
1.4
—
—
—
0
0
28
244
1.17
0.28
1.7
2.0
—
—
—
0
0
66
705
0.90
0.25
2.1
1.9
1.45
1.39
mmol/l
0.19
53
595
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
11.1
—
0.68
—
0
13
0
14
0.00
0.20
0.0
2.9
—
—
—
0
0
5
66
0.75
0.17
1.0
1.1
—
—
—
0
0
5
69
0.72
0.17
2.8
3.0
1.42
1.48
%
—
5
63
21
187
1.14
0.16
2.1
1.9
307.81
391.91
nmol/l
1.44
21
175
76
728
1.08
0.15
2.6
2.6
—
—
estimate
—
0
0
148
1504
0.91
0.14
5.2
5.0
5.97
5.94
mmol/l
0.07
131
1396
27
248
1.10
0.13
1.4
1.7
774.11
1178.90
nmol/l
2.09
18
190
9
105
0.85
0.13
1.6
1.2
—
—
—
0
0
52
546
0.93
0.12
3.3
4.0
5.01
9.19
mg/mmol
1.13
31
344
158
1560
1.10
0.12
5.9
5.1
4.77
4.64
mmol/l
0.94
143
1470
51
532
0.94
0.10
3.1
3.3
42.68
54.36
mg/l
0.30
31
348
157
1554
1.08
0.08
5.7
5.1
1.48
1.44
mmol/l
0.64
142
1455
8
76
1.06
0.07
3.5
3.6
—
—
—
0
0
9
83
1.09
0.07
1.3
1.7
—
—
—
0
0
9
87
1.04
0.07
2.6
4.7
—
—
—
0
0
37
357
1.05
0.05
3.0
4.0
1.01
1.02
kg/l
1.68
26
237
58
566
1.04
0.05
2.8
3.2
7.96
8.07
mmol/l
0.06
45
475
147
1476
0.98
0.00
6.4
6.3
38.84
39.38
mmol/mol
0.29
136
1409
20
197
1.02
0.00
1.3
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.6
—
2.16
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
2140.00
—
0
5
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
158
1580
1.00
-0.00
6.4
5.8
2.85
2.73
mmol/l
0.94
141
1485
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
59
1.02
-0.00
5.7
3.1
1.00
0.85
%
—
6
53
0
8
0.00
-0.00
0.0
1.1
—
183.00
—
0
8
0
9
0.00
-0.00
0.0
1.2
—
73.89
—
0
9
6
63
0.95
-0.00
4.2
3.4
1485.33
1162.41
u/ml
—
6
54
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
9
95
0.94
-0.00
1.2
1.2
—
123.09
—
0
34
0
6
0.00
-0.00
0.0
2.7
—
4.22
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
38.14
—
0
9
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
13.00
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_TICK_BORNE_ENCEPHALITIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have AB1_TICK_BORNE_ENCEPHALITIS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: AB1_TICK_BORNE_ENCEPHALITIS – Tick-borne viral encephalitis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data